Roche Pharmaceutical Research and Early Development, Pharmaceutical Sciences, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Bldg 93 Room 5.10, Grenzacherstrasse 124, 4070, Basel, CH, Switzerland.
Novartis Pharma AG, Novartis Institutes for Biomedical Research, Basel, Switzerland.
Pharm Res. 2018 Jun 27;35(9):169. doi: 10.1007/s11095-018-2448-8.
Administration of therapeutic monoclonal antibodies (mAbs) is frequently accompanied by severe first infusion reactions (FIR). The mechanism driving FIR is still unclear. This study aimed to investigate the cellular and molecular mechanisms causing FIR in humanized mouse models and their potential for evaluating FIR risk in patients.
Mice humanized for Fc gamma receptors (FcγRs) were generated by recombination-mediated genomic replacement. Body temperature, cytokine release and reactive oxygen species (ROS) were measured to assess FIR to mAbs.
Infusion of human mAb specific for mouse transferrin receptor (HamTfR) into FcγR-humanized mice, produced marked transient hypothermia accompanied by an increase in inflammatory cytokines KC and MIP-2, and ROS. FIR were dependent on administration route and Fc-triggered effector functions mediated by neutrophils. Human neutrophils also induced FIR in wild type mice infused with HamTfR. Specific knock-in mice demonstrated that human FcγRIIIb on neutrophils was both necessary and sufficient to cause FIR. FcγRIIIb-mediated FIR was abolished by depleting neutrophils or blocking FcγRIIIb with CD11b antibodies.
Human FcγRIIIb and neutrophils are primarily responsible for triggering FIR. Clinical strategies to prevent FIR in patients should focus on this pathway and may include transient depletion of neutrophils or blocking FcγRIIIb with specific mAbs.
治疗性单克隆抗体(mAb)的给药常伴有严重的首次输注反应(FIR)。导致 FIR 的机制仍不清楚。本研究旨在研究在人源化小鼠模型中引起 FIR 的细胞和分子机制及其在评估患者 FIR 风险中的潜力。
通过重组介导的基因组替换生成了人源化 Fcγ 受体(FcγR)的小鼠。通过测量体温、细胞因子释放和活性氧(ROS)来评估 mAb 引起的 FIR。
将针对小鼠转铁蛋白受体(HamTfR)的人源 mAb 输注到人源化 FcγR 小鼠中,会产生明显的短暂体温下降,伴有炎症细胞因子 KC 和 MIP-2 以及 ROS 的增加。FIR 依赖于给药途径和由中性粒细胞介导的 Fc 触发的效应功能。输注 HamTfR 的野生型小鼠中,人源中性粒细胞也会引起 FIR。特异性敲入小鼠表明,中性粒细胞上的人 FcγRIIIb 是引起 FIR 的必要和充分条件。用 CD11b 抗体耗尽中性粒细胞或阻断 FcγRIIIb 可消除 FcγRIIIb 介导的 FIR。
人源 FcγRIIIb 和中性粒细胞主要负责触发 FIR。预防患者 FIR 的临床策略应重点关注该途径,可能包括短暂耗尽中性粒细胞或使用特异性 mAb 阻断 FcγRIIIb。